IntelliPharmaCeutics reports Q2 results

• IntelliPharmaCeutics (OTC:IPCI +1.9%) Q2 results: Revenues: $0.6M (-53.8%); R&D Expense: $1.5M (-6.3%); SG&A: $0.9M (-10.0%); Operating Loss: ($1.9M) (-35.7%); Net Loss: ($2M) (-33.3%); Loss Per Share: ($0.08) (-33.3%); Quick Assets: $0.2M (-88.9%); CF Ops: ($1.3M) (-8.3%).
• No guidance given.